Document Detail


Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
MedLine Citation:
PMID:  9661139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin-converting enzyme (ACE) inhibitors are known to reduce blood pressure and proteinuria in a variety of different glomerular diseases. Nonetheless, a marked interindividual difference in the efficacy of these agents exists. The activity of the ACE and therefore of the renin-angiotensin-aldosterone system (RAAS) has been shown to be under genetic influence. Patients with a deletion genotype at the intron 16 of the ACE gene have been shown to exhibit higher activity of plasmatic ACE when compared to patients with the insertion genotype. We therefore studied prospectively the hemodynamic and antiproteinuric effect of a 6-month therapy with enalapril in patients with biopsy-proven proteinuric glomerular diseases and the DD (n = 10) and ID/II (n = 26) genotype. Although patients with the DD genotype received a slightly higher dose of enalapril, blood pressure and proteinuria did not change significantly. However, both were significantly reduced in the II/ID group after 10 weeks and 6 months of therapy. Creatinine clearance decreased steadily in DD patients. In II/ID patients, creatinine clearance was reduced significantly after 10 weeks of therapy but increased again thereafter and the value at 6 months was again comparable to the one obtained in the DD patients. We conclude from our study that the ACE genotype influences the blood pressure-lowering and antiproteinuric effect of enalapril in patients with proteinuric glomerular disease.
Authors:
M Haas; N Yilmaz; A Schmidt; U Neyer; K Arneitz; H K Stummvoll; M Wallner; M Auinger; I Arias; B Schneider; G Mayer
Related Documents :
10555419 - Obstructive nephropathy due to sulfa crystals in two hiv seropositive patients treated ...
9090749 - Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of meta...
4048389 - Microscopic polyarteritis: presentation, pathology and prognosis.
7696109 - Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in ital...
7679919 - Ultrastructural alteration of glomerular anionic sites in nephrotic patients.
2113219 - Acute interstitial nephritis: a clinical and morphological study in 27 patients.
16143569 - Epilepsy surgery in professional musicians: subjective and objective reports of three c...
21296899 - The perfect crime? ccsvi not leaving a trace in ms.
21396679 - Heterogeneous pattern of renal disease associated with homozygous factor h deficiency.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kidney & blood pressure research     Volume:  21     ISSN:  1420-4096     ISO Abbreviation:  Kidney Blood Press. Res.     Publication Date:  1998  
Date Detail:
Created Date:  1998-09-21     Completed Date:  1998-09-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9610505     Medline TA:  Kidney Blood Press Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  66-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine III, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Creatinine / metabolism
DNA / analysis
Enalapril / therapeutic use*
Female
Follow-Up Studies
Genotype
Hemodynamics / drug effects*
Humans
Male
Middle Aged
Peptidyl-Dipeptidase A / drug effects,  genetics*
Polymerase Chain Reaction
Polymorphism, Genetic*
Prospective Studies
Proteinuria / drug therapy,  metabolism*,  physiopathology
Sodium / urine
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 60-27-5/Creatinine; 7440-23-5/Sodium; 75847-73-3/Enalapril; 9007-49-2/DNA; EC 3.4.15.1/Peptidyl-Dipeptidase A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
Next Document:  Ambulatory infusion of noradrenaline for long-term treatment of Shy-Drager syndrome.